Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Rhea-AI Summary

Ocugen (NASDAQ: OCGN)/b) reported positive 12-month Phase 2 ArMaDa results for in geographic atrophy (GA) secondary to dry AMD. The medium (optimal) dose showed a 31% reduction in lesion growth versus control (p<0.05) and 27% slower ellipsoid zone loss, with no OCU410-related serious adverse events reported. The 51-patient trial randomized subjects 1:1:1 (medium, high, control). Ocugen plans a Phase 3 registrational trial in Q3 2026 with up to 300 subjects and an adaptive design powered >95%.

Positive

• Lesion growth -31% in medium dose vs control at 12 months
• EZ preservation +27% slower ellipsoid zone loss vs control
• 55% of treated patients showed ≥30% lesion reduction
• No OCU410-related serious adverse events reported to date
• Phase 3 planned Q3 2026 with up to 300 subjects, adaptive design

Negative

• Small Phase 2 sample size of 51 patients limits broader generalizability
• Heterogeneous population permitted prior complement therapy and fellow-eye CNV, which may increase variability

News Market Reaction – OCGN

-8.57%

19 alerts

-8.57% News Effect

-23.3% Trough in 23 min

-$65M Valuation Impact

$692M Market Cap

0.5x Rel. Volume

On the day this news was published, OCGN declined 8.57%, reflecting a notable negative market reaction. Argus tracked a trough of -23.3% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $65M from the company's valuation, bringing the market cap to $692M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Lesion growth reduction: 31% EZ loss reduction: 27% Responder rate: 55% +5 more

8 metrics

Lesion growth reduction 31% OCU410 optimal dose vs control at 12 months (p<0.05)

EZ loss reduction 27% Slower rate of ellipsoid zone loss vs control

Responder rate 55% Treated patients with ≥30% lesion size reduction vs control

Subgroup lesion reduction 33% Baseline GA lesions ≥5 mm² and ≤17.5 mm², medium dose vs control

Phase 2 sample size 51 patients GA secondary to dry AMD, randomized 1:1:1

Medium dose level 1 × 10^10 vector genomes/eye Single subretinal OCU410 administration, medium dose

High dose level 3 × 10^10 vector genomes/eye Single subretinal OCU410 administration, high dose

Planned Phase 3 size up to 300 subjects Anticipated Phase 3 OCU410 pivotal trial, adaptive design

Market Reality Check

Price: $1.95 Vol: Volume 13,493,269 is slig...

normal vol

$1.95 Last Close

Volume Volume 13,493,269 is slightly above the 20-day average of 12,356,645 (relative volume 1.09x). normal

Technical Price $2.10 trades above the 200-day MA at $1.37 and about 22.94% below the 52-week high of $2.725.

Peers on Argus

OCGN is up 2.94% with modestly elevated volume. Three biotech peers (e.g., MBX, ...

3 Up

OCGN is up 2.94% with modestly elevated volume. Three biotech peers (e.g., MBX, RCKT, ALT) also appear on the momentum scanner, each moving up around 2%, consistent with the note that 3 peers on Argus are also moving higher.

Common Catalyst Sector-wide positive momentum in biotech/gene therapy names without peer-specific news headlines.

Previous Clinical trial Reports

5 past events · Latest: Mar 23 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 23	Webcast announcement	Neutral	+2.9%	Company scheduled webcast to review full Phase 2 OCU410 data.
Mar 02	Phase 3 enrollment	Positive	+6.6%	Completed Phase 3 liMeliGhT enrollment for OCU400 in retinitis pigmentosa.
Jan 15	Phase 2 data update	Positive	-13.8%	Reported positive preliminary 12‑month Phase 2 OCU410 data in GA.
Jan 13	Webcast announcement	Neutral	+7.3%	Announced webcast to discuss first set of OCU410 Phase 2 data.
Jan 12	Phase 1 results	Positive	+18.7%	Published positive Phase 1 GARDian1 results for OCU410ST in Stargardt disease.

Pattern Detected

Clinical trial updates have often generated strong moves, with mostly positive reactions but one notable negative response to earlier OCU410 data.

Recent Company History

Over recent months, Ocugen has repeatedly highlighted clinical progress in its modifier gene therapy pipeline. Prior clinical trial news included Phase 1 GARDian1 data for OCU410ST, preliminary Phase 2 ArMaDa results for OCU410, and Phase 3 liMeliGhT enrollment completion for OCU400. These events generally produced single‑ to double‑digit price moves. Today’s 12‑month OCU410 Phase 2 data continue this theme of advancing retinal gene therapies toward planned Phase 3 trials and future BLAs.

Historical Comparison

+4.3% avg move · In past 12 months, OCGN’s clinical‑trial headlines saw an average 4.33% 1‑day move. Today’s pre‑data...

clinical trial

+4.3%

Average Historical Move clinical trial

In past 12 months, OCGN’s clinical‑trial headlines saw an average 4.33% 1‑day move. Today’s pre‑data gain of 2.94% sits below that typical reaction.

Clinical updates show a progression from Phase 1 OCU410ST data to preliminary and now fuller Phase 2 OCU410 results, alongside Phase 3 enrollment completion for OCU400.

Market Pulse Summary

The stock moved -8.6% in the session following this news. A negative reaction despite encouraging OC...

Analysis

The stock moved -8.6% in the session following this news. A negative reaction despite encouraging OCU410 lesion‑reduction data would fit a pattern seen once before, when earlier positive Phase 2 results coincided with a double‑digit percentage decline. Such divergence highlights how financing needs, prior dilution, or profit‑taking can outweigh trial progress. Historical clinical headlines have usually been met with gains, so a sustained downside move would mark a departure from the average 4.33% rise.

Key Terms

modifier gene therapy, geographic atrophy, dry age-related macular degeneration, ellipsoid zone, +4 more

8 terms

modifier gene therapy medical

"OCU410 (AAV5-RORA), its novel modifier gene therapy for geographic atrophy"

Modifier gene therapy is a treatment that changes the activity of genes that influence how severe or how a disease progresses, rather than directly fixing the original faulty gene. Think of it as turning a volume knob on disease symptoms: it can make conditions milder or slow progression, which matters to investors because it can expand the number of patients who benefit, affect how quickly and cheaply a product can reach the market, and change commercial and regulatory risk and reward.

geographic atrophy medical

"modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration"

Geographic atrophy is a progressive eye condition in which patches of light-sensing cells in the retina die, causing growing blind spots and ultimately significant central vision loss. For investors, it matters because the condition defines the market size and urgency for drugs, devices, and diagnostics — like a spreading hole in a photograph that companies aim to stop or repair — so clinical results, approvals, and reimbursement determine potential revenue and risk.

dry age-related macular degeneration medical

"geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD)"

Dry age-related macular degeneration is a progressive eye disease in which the central part of the retina (the macula) slowly loses light-sensing cells, leading to gradual blurring or loss of central vision like a camera with a worn-out sensor. It matters to investors because the condition affects a large and growing population, creates demand for diagnostics, treatments and long-term care, and clinical or regulatory developments can significantly influence companies' revenues and stock prices.

ellipsoid zone medical

"27% slower rate of ellipsoid zone (EZ) loss compared to control"

A bright, thin layer seen on a retinal scan (OCT) that represents part of the light-sensing cells in the eye; it acts like an indicator light for the cells that convert light into vision. Its integrity correlates with how well someone can see, so changes are used as objective biomarkers in clinical trials and regulatory assessments and matter to investors because they help predict treatment effectiveness and market value of eye therapies.

photoreceptors medical

"indicating structural preservation of photoreceptors, which correlates with visual function"

Photoreceptors are specialized cells in the eye that detect light and convert it into electrical signals the brain uses to create vision; think of them as the camera sensor inside your eye. They matter to investors because therapies, devices, or drugs that repair, replace, or protect photoreceptors can address large unmet medical needs, influence regulatory approvals, and open significant markets in ophthalmology and biotechnology.

fundus autofluorescence medical

"measured in square millimeters by fundus autofluorescence, an FDA-accepted structural endpoint"

Fundus autofluorescence is a noninvasive eye imaging method that captures natural glow from molecules in the retina to create a map of tissue health and disease-related changes. For investors, it matters because this objective, repeatable scan is often used in clinical trials and medical monitoring to show whether an eye therapy is slowing damage or improving tissue, much like a before-and-after photo that reveals hidden changes over time.

intravitreal injections medical

"current therapies require 6–12 injections per year indefinitely...intravitreal injections"

An intravitreal injection is a medical procedure that delivers medication directly into the eye’s vitreous, the clear gel at the back of the eyeball, to treat retinal and other internal eye conditions. For investors it matters because these injections create recurring demand for specialty drugs, delivery tools and clinic services; treatment frequency, safety and reimbursement determine revenue size and predictability, similar to a subscription product for vision care.

biologics license applications regulatory

"goal of three BLA filings in three years"

A biologics license application is a formal request submitted to a regulatory agency to get permission to market a biological medicine—such as vaccines, blood products, or gene and cell therapies—after clinical testing. It’s like applying for a safety and quality permit that lets a company sell a complex medical product; investors watch its progress because approval clears the way for revenue while rejection or delays create significant financial risk.

AI-generated analysis. Not financial advice.

• Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)
• Potential 2X treatment benefit compared to 15% and 22% reductions reported for currently approved therapies at 12 and 24 months, respectively
• No serious adverse events and no adverse events of special interest related to OCU410 reported to date
  

MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positive 12-month data from the Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV5-RORA), its novel modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). The global prevalence of dAMD is 266 million worldwide, and GA affects approximately 2-3 million people in the United States (U.S.) and Europe. Importantly, this number is expected to increase significantly as populations age.

There are limited options for patients with dAMD in the U.S. and current therapies require 6–12 injections per year indefinitely, leading to substantial burden and significant dropout rates in real-world practice. Outside of the U.S., there are no approved products available.

Key findings from Phase 2 include:

• 31% reduction in lesion growth in the optimal dose (medium) group compared to control (p< 0.05)
• 27% slower rate of ellipsoid zone (EZ) loss compared to control, indicating structural preservation of photoreceptors, which correlates with visual function
• 55% of treated patients demonstrated ≥30% lesion size reduction vs. control
• Subgroup analysis (subjects with baseline GA lesions ≥5 mm² and ≤17.5 mm²) showed 33% reduction in lesion growth compared to control in medium dose OCU410 with similar reductions in the high dose group

The Phase 2 clinical trial builds directly on the clean safety profile observed in Phase 1 with no OCU410-related serious adverse events observed and no cases of endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ischemic optic neuropathy reported to date.

GA is a multifactorial disease with a complex etiology that involves genetic and environmental factors. The current treatment options for GA in the U.S. are limited to those targeting a single mechanism—the complement pathway. By contrast, OCU410 is a first-in-class RORA-based gene therapy designed to support central retina and photoreceptor integrity through a multi-pathway mechanism—targeting drusen, inflammation, oxidative stress, and complement activation.​

“We have confirmed robust treatment effect from a well-controlled Phase 2 trial of a genetic medicine for GA. Now we can move on to Phase 3 with a high degree of confidence,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “This moves us one step closer to bringing a transformative one-time treatment to GA patients globally who are desperately seeking rescue from vision loss.”

“Our Phase 2 data consistently demonstrates statistically significant reduction of GA lesion growth after treatment with OCU410 optimal dose, and we continue to benchmark these results against natural history data to contextualize the magnitude of effect,” said Huma Qamar, MD, MPH, CMI, Chief Medical Officer of Ocugen. “We are incorporating these learnings into an anticipated Phase 3 pivotal confirmatory trial with up to 300 subjects and an adaptive design powered at over 95%.​”

“There remains a considerable unmet need in treating patients with GA and I am encouraged by the various analyses of the Phase 2 OCU410 data,” said Lejla Vajzovic, MD, FASRS, Director, Duke Surgical Vitreoretinal Fellowship Program, Associate Professor of Ophthalmology with Tenure, Adult and Pediatric Vitreoretinal Surgery and Disease, Duke University Eye Center, and Chair, Ocugen Retina Scientific Advisory Board. “In addition to the strong efficacy and safety data, OCU410 has the potential to eliminate the chronic treatment burden associated with monthly or every-other-month intravitreal injections and to reduce treatment attrition driven by patient fatigue.​”

In the Phase 2 study, the safety and efficacy of OCU410 in patients with GA secondary to dAMD are being assessed. Fifty-one (51) patients aged 50 years and older with GA lesions within the foveal or non-foveal region were randomized 1:1:1 to receive a single subretinal administration of OCU410 at a medium dose of 1 × 10¹⁰ vector genomes per eye, a high dose of 3 × 10¹⁰ vector genomes per eye, or no treatment in the control group; each injection volume was 200 microliters. Of note, choroidal neovascularization in the fellow eye was not exclusionary, and patients with prior exposure to pegcetacoplan or avacincaptad pegol were eligible following a three-month washout.

The primary endpoint was change in GA lesion size at 12 months, measured in square millimeters by fundus autofluorescence, an FDA-accepted structural endpoint used in recent GA registration trials. Exploratory endpoints included EZ preservation on OCT a key biomarker for photoreceptor integrity, which correlates with visual function.

Ocugen plans to initiate the OCU410 Phase 3 registrational trial in the third quarter of 2026 in line with the Company’s goal of three BLA filings in three years.

About dAMD and Geographic Atrophy
Geographic atrophy is an advanced form of dAMD characterized by progressive degeneration of the macula, leading to irreversible central vision loss. Millions of patients worldwide are affected by GA, with a particularly high burden in aging populations in the United States and Europe. Despite recent approvals, treatment options remain limited and require chronic intravitreal injections, underscoring the need for innovative, durable therapies that address multiple disease mechanisms. dAMD affects approximately 10 million Americans and more than 266 million people worldwide. It is characterized by the thinning of the macula, the portion of the retina responsible for clear vision in one’s direct line of sight. dAMD involves the slow deterioration of the retina with submacular drusen (small white or yellow dots on the retina), atrophy, loss of macular function, and central vision impairment. dAMD accounts for 85-90% of all AMD cases.

About OCU410
OCU410 is an investigational, subretinal injection, AAV5-based gene therapy that delivers RORA (retinoid-related orphan receptor alpha), a nuclear receptor that regulates key pathways involved in retinal homeostasis, including oxidative stress response, complement regulation, inflammation, and lipid metabolism. OCU410 is being developed as a one-time gene therapy for patients with GA secondary to dry AMD. OCU410 has received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; the ability of OCU410 to perform in humans in a manner consistent with nonclinical, preclinical or previous clinical study data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com

FAQ

What were the 12-month Phase 2 ArMaDa results for Ocugen OCGN's OCU410?

The medium dose achieved a 31% reduction in GA lesion growth versus control (p<0.05). According to the company, additional endpoints showed 27% slower ellipsoid zone loss and 55% of treated patients had ≥30% lesion reduction.

How safe was OCU410 in the Phase 2 ArMaDa trial for OCGN?

No OCU410-related serious adverse events were reported in the trial to date. According to the company, there were no cases of endophthalmitis, retinal detachment, vasculitis, choroidal neovascularization, or ischemic optic neuropathy reported.

What is the planned Phase 3 timeline for Ocugen OCGN's OCU410?

Ocugen plans to start the Phase 3 registrational trial in Q3 2026 with up to 300 subjects. According to the company, the trial will use an adaptive design powered at over 95%.

What dose and administration were used in the OCU410 Phase 2 ArMaDa trial (OCGN)?

Patients received a single subretinal administration of OCU410 at medium (1×10^10 vg/eye) or high (3×10^10 vg/eye) doses. According to the company, each injection volume was 200 microliters.

How does OCU410's effect compare to existing GA therapies for OCGN?

Ocugen reported a potential ~2X treatment benefit versus reported 15–22% reductions for approved therapies at 12–24 months. According to the company, OCU410 targets multi-pathway mechanisms beyond complement inhibition.

Who was eligible for Ocugen OCGN's Phase 2 ArMaDa study and what was the primary endpoint?

Fifty-one patients aged ≥50 with GA lesions were randomized 1:1:1 to medium, high, or control arms. According to the company, the primary endpoint was change in GA lesion size at 12 months by fundus autofluorescence.